These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36908162)

  • 21. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacology of modern anti-arrhythmia drugs in therapy of supraventricular tachycardia].
    Honerjäger P; Schmidt G
    Z Gesamte Inn Med; 1993 Sep; 48(9):425-9. PubMed ID: 8212747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Valembois L; Audureau E; Takeda A; Jarzebowski W; Belmin J; Lafuente-Lafuente C
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD005049. PubMed ID: 31483500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials.
    Ibrahim OA; Belley-Côté EP; Um KJ; Baranchuk A; Benz AP; Dalmia S; Wang CN; Alhazzani W; Conen D; Devereaux PJ; Whitlock RP; Healey JS; McIntyre WF
    Europace; 2021 Aug; 23(8):1200-1210. PubMed ID: 33723602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flecainide: Electrophysiological properties, clinical indications, and practical aspects.
    Paolini E; Stronati G; Guerra F; Capucci A
    Pharmacol Res; 2019 Oct; 148():104443. PubMed ID: 31493514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of patients with acute atrial fibrillation in the ED.
    Conti A; Del Taglia B; Mariannini Y; Pepe G; Vanni S; Grifoni S; Abbate R; Michelucci A; Padeletti L; Gensini GF
    Am J Emerg Med; 2010 Oct; 28(8):903-10. PubMed ID: 20825922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
    Taylor R; Gandhi MM; Lloyd G
    BMJ; 2010 Mar; 340():b4684. PubMed ID: 20219811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with propafenone for cardiac arrhythmias in the young.
    Heusch A; Kramer HH; Krogmann ON; Rammos S; Bourgeous M
    Eur Heart J; 1994 Aug; 15(8):1050-6. PubMed ID: 7527342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.
    Camm AJ; Hellestrand KJ; Nathan AW; Bexton RS
    Drugs; 1985; 29 Suppl 4():7-13. PubMed ID: 4006783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Class IC drugs: propafenone and flecainide.
    Puech P; Gagnol JP
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():549-53. PubMed ID: 2125832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines for the use of propafenone in treating supraventricular arrhythmias.
    Kishore AG; Camm AJ
    Drugs; 1995 Aug; 50(2):250-62. PubMed ID: 8521758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias.
    Lavalle C; Magnocavallo M; Straito M; Santini L; Forleo GB; Grimaldi M; Badagliacca R; Lanata L; Ricci RP
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33918105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation.
    Marcus FI
    Am J Cardiol; 1990 Aug; 66(3):366-7. PubMed ID: 2114783
    [No Abstract]   [Full Text] [Related]  

  • 34. A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
    Eur Heart J; 1992 Sep; 13(9):1251-8. PubMed ID: 1396837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased milk drinking causing flecainide toxicity in an older child.
    Thompson B; Mangat J; Barton C; Hawcutt DB
    BMJ Case Rep; 2012 Jun; 2012():. PubMed ID: 22729333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
    Pritchett EL; Wilkinson WE
    Am J Cardiol; 1991 May; 67(11):976-80. PubMed ID: 1902055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of flecainide.
    Tamargo J; Capucci A; Mabo P
    Drug Saf; 2012 Apr; 35(4):273-89. PubMed ID: 22435343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
    Rae AP
    Am J Cardiol; 1998 Oct; 82(8A):59N-65N. PubMed ID: 9809902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
    Bryson HM; Palmer KJ; Langtry HD; Fitton A
    Drugs; 1993 Jan; 45(1):85-130. PubMed ID: 7680987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transesophageal electropharmacologic testing.
    Furlanello F; Guarnerio M; Inama G; Vergara G; Del Greco M; Bertoldi A; Dallago M
    Am J Cardiol; 1992 Aug; 70(5):19A-25A. PubMed ID: 1509994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.